Barclays Maintains Overweight on Danaher, Raises Price Target to $260
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Overweight and raises the price target from $255 to $260.
Barclays analyst Luke Sergott maintains Danaher (NYSE:DHR) with a Overweight and raises the price target from $255 to $260.
More on DHR
FDA & biotech Benzinga
Danaher Unveils Microsoft AI Partnership to Accelerate Scientific ExperimentsDanaher partners with Microsoft to build AI scientific instruments on Azure and Foundry, cutting lab experiment times by up to 83%.

Benzinga
Danaher Enters Strategic Partnership With Microsoft To Develop Smart Scientific Instruments And Interoperable Agentic Ecosystem To Connect TechnologiesThe partnership seeks to combine Danaher's scientific, workflow and instrumentation expertise with Microsoft's AI technologies, making experimental execution more streamlined and insights more…
